Structure of QnrB1, a plasmid-mediated fluoroquinolone resistance factor*

Matthew W. Vetting1, Subray S. Hegde1, Minghua Wang2, George A. Jacoby3, David C. Hooper2, John S. Blanchard1*

1Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461 2Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, 3Lahey Clinic, Burlington, MA 01805

Running head: Structure of QnrB1
Address correspondence to: John S. Blanchard, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461; phone: (718) 430-3096, Fax: (718) 430-8565; E-mail: blanchar@aecom.yu.edu

QnrB1 is a plasmid-encoded pentapeptide repeat protein (PRP) that confers a moderate degree of resistance to fluoroquinolones. Its gene was cloned into an expression vector with an N-terminal polyhistidine tag, and the protein was purified by nickel affinity chromatography. The structure of QnrB1 was determined by a combination of trypsinolysis, surface mutagenesis, and single anomalous dispersion phasing. QnrB1 folds as a right-handed quadrilateral β-helix with a highly asymmetric dimeric structure typical of pentapeptide repeat protein topoisomerase-poison resistance factors (PRP-TPRF). The threading of pentapeptides into the β-helical fold is interrupted by two non-canonical PRP sequences that produce outward projecting loops that interrupt the regularity of the PRP surface. Deletion of the larger upper loop eliminated the protective effect of QnrB1 on DNA gyrase towards inhibition by quinolones, while deletion of the smaller lower loop drastically reduced the protective effect. These loops are conserved among all plasmid-based Qnr variants (QnrA, QnrC, QnrD, QnrS) and some chromosomally encoded Qnr varieties. A mechanism in which PRP-TPRFs bind to and disrupt the quinolone-DNA-gyrase interaction is proposed.

Qnr proteins are members of the pentapeptide repeat protein (PRP) family that bind to and protect DNA gyrase and topoisomerase IV from inhibition by quinolones resulting in reduced susceptibility to this important class of antimicrobial agents (1-3). They have been found encoded by multiresistant plasmids in isolates of Enterobacteriaceae from around the world and may also be identifiable genes on the bacterial chromosome (4). Although quinolone resistance conferred by Qnr proteins is modest, their presence promotes selection of higher levels of resistance in vitro and in vivo (5-8). Five Qnr families (A, B, C, D, and S) are currently recognized (5,9-12) with QnrB having the highest prevalence, the greatest number of alleles (more than 30), and the earliest documented discovery (13,14). QnrB is also unique in being under control by the SOS system so that DNA damage produced by quinolones, such as ciprofloxacin, induces its expression by relief of binding to a LexA recognition site upstream from qnrB genes (12,15).

Other pentapeptide repeat proteins (PRPs) protect against different topoisomerase poisons. For example AlbG protects the sugarcane pathogen Xanthomonas albilineans against the albicidin family of antibiotics that it produces and which, like quinolones, are potent inhibitors of DNA gyrase supercoiling (16). McbG is a PRP made for self-protection by producers of microcin B17, a protein topoisomerase poison (17,18). Finally, MfpA is a PRP encoded on the chromosome of Mycobacterium tuberculosis and other mycobacteria. Deletion of MfpA increases quinolone susceptibility and augmenting its expression by cloning on a multicopy plasmid reduces susceptibility (19), although in a cell-free system MfpA lacks quinolone protective activity and only inhibits DNA gyrase at concentrations between 1 and 5 µM (20,21)

The crystal structure of MfpA suggested a model for its activity (20). MfpA is a dimer with each monomer almost entirely in the form of a
right-handed β helix stabilized by hydrogen bonding between backbone atoms of neighboring coils and with a negative electrostatic surface potential. It thus has features similar to DNA and therefore was proposed to dock against the highly cationic saddle region at the gyrase A₂ dimer interface displacing DNA. MfpA and by inference other PRPs were therefore proposed to act by inhibiting the formation of the quinolone DNA-gyrase covalent complex, preventing DNA damage.

In contrast to MfpA, QnrB₁ protects DNA gyrase from ciprofloxacin at concentrations as low as 5 pM and only inhibits DNA gyrase at high concentrations (>25 µM) (10). QnrB₁ is a superior model system for study of PRP-topoisomerase-poison resistance factors (TPRFs) as its in vitro activities are consistent with the in vivo protective effects of PRP-TPRFs and are similar to the majority of PRP-TPRFs. We report here the structure of QnrB₁ by x-ray crystallography and propose a model to explain its protective and inhibitory actions on topoisomerases.

**EXPERIMENTAL PROCEDURES**

**Cloning, Expression and Purification –** QnrB₁ was PCR amplified utilizing plasmid pMG298 (10) as a template, 5’-GGGAATTCCATATGACGCCATTACTGTATAAAAAAACAGGTA:3’ and 5’-CGCGGATCCCTAACCAATCACCGCGAT:3’ as primers and subsequently cloned into the Nde₁, BamHI site of pET28a (Novagen). QnrB₁ mutants were produced using QUICKCHANGE mutagenesis (STRATAGENE) and plasmid pET28a:QnrB₁. For the M102R mutant the primers were 5’-CGCGGCGCAAGCTTTAGGATATGATCACCACG:3’ and 5’-CGTGGTGATCATATTCCTAAAGCTTGCGCCGCG:3’ and for R167E were 5’-CGACTTTCGAACTGGGAAAGCAGCAGCAAACTTCAC:3’ and 5’-GTGAAGTTTGCTGCTTCCCAGTCGAAAGTCG:3’. QnrB₁ was expressed by autoinduction using standard protocols (22,23). Briefly, plasmid QnrB₁ was transformed into BL21DE3 and plated on LB-Agar containing 100 µg ml⁻¹ kanamycin. Four to six colonies were transferred to 75 ml of LB containing the same concentration of kanamycin and shaken (300 rpm) overnight at 37°C. The overnight culture was used to inoculate 10 2 L baffled flasks, each containing 400 ml of autoinduction media (23). The flasks were shaken (300 rpm) for 6 h at 37°C, then at 23°C for an additional 24-36 h. Cells were harvested by centrifugation and stored at –80°C. Cell paste was resuspended to 3 times the volume with buffer A (50 mM Tris pH 8.0, 200 mM (NH₄)₂SO₄, 10% glycerol, 20 mM imidazole) supplemented with 1 mg ml⁻¹ lysozyme, 0.1 mg ml⁻¹ DNase and 0.5% Triton-X 100. Following sonication and clarification by centrifugation (both at 4°C), the supernatant was applied to a 2.5 x 15 cm Ni:NTA column (maintained at 20°C) that had been equilibrated against buffer A. The column was washed extensively with buffer A, and proteins were eluted with buffer B (50 mM Tris pH 8.0, 200 mM (NH₄)₂SO₄, 10% glycerol, 300 mM imidazole). The collected elutant was immediately aliquoted, snap frozen in liquid N₂, and stored at -80°C.

**Structure:** Based loop deletion mutants; viz.

loop A deletion (ΔY₄₆-Q₅₁) mutant, loop B deletion (ΔM₁₀₄-S₁₁₃) mutant and loop AB double deletion (ΔY₄₆-Q₅₁ and ΔM₁₀₄-S₁₁₃) mutant were constructed using overlap extension PCR, cloned, expressed and purified as described above. Desired deletions and the absence of any other mutations were confirmed by the DNA sequencing of the cloned constructs.

**Trypsin Treatment** - Protein (at 10-20 mg ml⁻¹ in buffer B) was thawed from −80°C storage and dialyzed overnight against storage buffer C (20 mM Tris pH 8.0, 10 glycerol, 50 mM arginine) with the addition of trypsin (SIGMA T₁₀₀₅, 1 to 500 w/w ratio). Retention of an oligomeric state and protein mass was monitored by size exclusion chromatography on a 2.5 X 100 cm SEPHEDEX column (PHARMACIA) with samples compared against gel filtration standards. Trypsin-treated protein was immediately utilized for crystallization or snap frozen in liquid N₂ and stored at −80°C.

**Crystallization-** (Wild type) Protein was dialyzed overnight against storage buffer C at a protein concentration < 1 mg ml⁻¹. Protein was concentrated by ultracentrifugation to 4 mg ml⁻¹ and utilized immediately for crystallization.
Crystallization was by vapour diffusion under oil utilizing 2 + 2 μl (reservoir + protein) drops under 150 μl of silicon oil (Fisher Scientific) in 96-well plates stored open to room humidity. Wild type QnrB1 crystallized as hexagonal plates in 100 mM Na/K phosphate pH 4.5, 2 M NaCl at 4°C. (M102R) Trypsin-treated M102R (10 mg ml⁻¹) crystallized as thick tetragonal rods in 100 mM Citrate/Phosphate pH 4.5, 1 M (NH₄)₂SO₄ at 20° C. (R167E) Trypsin-treated R167E (10 mg ml⁻¹) crystallized as irregular wedges in 100 mM BisTrisPropane/Citrate pH 7.5, 15% Peg3350 at 20° C. Structure determination- (M102R) Crystals of M102R were soaked in 100mM Na acetate pH 4.5, 1 M (NH₄)₂SO₄, 28% glycerol, 100 mM diethylenetriaminopentaacetic acid GdIII (DTPA) for 5 min prior to vitrification in liquid N₂. Data were generated on a RU-200/R-axis IV++ (Rigaku) and processed using MOSFLM (24) and CCP4 (25). The data were non-isomorphous with native data so phases were calculated using single anomalous dispersion (SAD). A single DTPA binding site was found by PHENIX (26) and the resultant SAD-solvent flattened phased map was submitted to autobuilding by ARP/WARP (27). The significantly built model (>75%) was completed by iterative cycles of fitting in COOT (28) and refinement in PHENIX. A high resolution M102R data set was collected on beamline X25 at NSLS and processed with HKL3000. There is a dimer in the asymmetric unit with a solvent content of 65%. (E167R) Crystals of E167R were cryoprotected in 100 mM BisTrisPropane/Citrate pH 7.5, 30% Peg3350 and vitrified by liquid N₂. Data were collected on beamline X25 at NSLS and processed with MOSFLM and CCP4. The structure was determined by molecular replacement within PHENIX utilizing a single M102R subunit as the search model. There is a dimer per asymmetric unit with a solvent content of 42%. (Wild Type) Crystals of QNRB1 WT were transferred to 100 mM K/Na phosphate, 2M NaCl, 30% glycerol for twenty minutes and vitrified by liquid N₂. Data were generated on a RU-200/R-axis IV++ and processed using MOSFLM and CCP4. The structure was determined by molecular replacement within PHENIX utilizing the M102R dimer as the search model. There is a tetramer per asymmetric unit with solvent content of 48%. Data collection and refinement statistics are listed in Table 1. Computation of buried surface area at the dimer interface was calculated in PISA (29). Structure figures were synthesized within PDB (30). Atomic coordinates and experimental structure factors for QnrB1 WT, QnrB1 M102R, and QnrB1 R167E have been deposited in the PDB (PDBID 2xtw, 2xtx, 2xty). Gyrase assays: DNA supercoiling assays were performed using E. coli gyrase assay kits (Inspiralis) according to manufacturer’s instructions. The reaction mixture containing 3 units ( a unit is defined as the amount of gyrase required to convert 0.5 μg of relaxed pBR322 into completely supercoiled form at 37 °C in 30 minutes) of gyrase and 0.4 μg relaxed DNA in a volume of 30 μl in gyrase assay buffer (35 mM Tris-HCl (pH 7.5), 24 mM KCl, 4 mM MgCl₂, 2 mM DTT, 1.8 mM spermidine, 1 mM ATP, 6.5% glycerol and 0.1 mg ml⁻¹ BSA) was incubated at 37 °C for 30 min and QnrB1 (WT and deletion mutant forms), ciprofloxacin and novobiocin were included where appropriate. Reactions were terminated by the addition of 30 μl chloroform/iso-amyl alcohol (24/1). The resulting topoisomers were separated by agarose gel electrophoresis, stained with ethidium bromide and visualized under UV light. For cleavage complex stabilization assays 6 units of gyrase was used and the assays were performed as described above. The reactions were terminated by the addition of 0.2% SDS and the mixtures were further incubated with proteinase K (0.1 mg ml⁻¹) for 30 min at 37 °C before chloroform/iso-amyl alcohol extraction and agarose gel electrophoresis. Inhibition and/or protection were calculated from band intensities using Syngene Bioimage analysis software.

RESULTS

QnrB1 was expressed with a thrombin-cleavable N-terminal hexahistidine (6X-His) tag. Expression of soluble protein was very high with yields after Ni-NTA elution of approximately 25 mg gm⁻¹ of cell paste. QnrB1 required immediate dilution to < 1 mg ml⁻¹ in buffers containing 10% glycerol and 50 mM arginine (buffer C; see methods) to remain soluble. Alternatively, the Ni-NTA eluting fractions could be snap frozen and stored at -80°
C, or diluted to 50% glycerol and stored at -20°C. QnrB1 co-eluted with the 44 kd gel filtration marker on size exclusion chromatography (SEC), consistent with QnrB1 being a molecular dimer (expected, 50 kd).

QnrB1 with 6X-His tag, in buffer C, and briefly raised to 4 mg ml⁻¹ formed crystals in a single condition at 4°C (see methods). A dataset was collected to 2.8 Å, but this crystal form was not consistently reproducible. Removal of the 6X-His tag produced thin needles in a number of conditions, but none produced useful diffraction.

Attempts were made to increase the solubility of QnrB1 by altering its surface characteristics and in parallel influence crystallization space. PRPs are excellent candidates for effective surface modification (31-33) as a priori to the structure we know the i⁻¹, i⁻² and i⁻³ residues are solvent-exposed (34). In preliminary experiments hydrophobic residues were converted to arginines (M60R, L82R, M102R, C112R, V130R, L82R/M102R, L82R/V130R) in an attempt to increase the surface charge. In another experiment, lysines and arginines were converted to glutamates (K52E, R87E, R167E), since glutamates exhibit improved solvation properties (35). After overnight dialysis with 1U/mg thrombin in 20 mM Tris pH 8.0, 200 mM ammonium sulfate all of the hydrophobic-to-arginine mutants were less soluble than wild type. In contrast, all three lysine/arginine-to-glutamate mutants were at least as soluble as wild type, with the K52E and R167E stable for at least a week at 10-15 mg ml⁻¹. Some of the mutants produced favorable improvement in the dimensions of the previously obtained needle-shaped crystal form, but they did not improve their diffraction characteristics.

Coincident with these experiments it was observed that treatment of precipitated QnrB1 with trypsin resulted in its solubilization. SDS polyacrylamide electrophoresis suggested that trypsin had removed the N-terminal tag and clipped the protein at least once, and possibly twice, within the main body of the protein. On size exclusion chromatography however, the trypsin-treated protein remained a similarly sized dimer, suggesting that the clipping was at points that did not affect the cohesion of the protein structure. Crystal trials were reinitiated with trypsin-treated protein wherein trypsin was added to the various constructs in a 1 to 500 w/w ratio in overnight dialysis against buffer C. Two of the mutants, M102R and R167E produced crystals that were suitable for structure determination. The R167E mutant diffracted to the highest resolution (1.8Å) but was non-ideal due to a long cell axis (282 Å); therefore, the M102R mutant (2.2Å) was utilized, and its structure determined by single anomalous dispersion from a gadolinium derivative. The high resolution structure of the R167E mutant and of uncleaved QnrB1 (2.8Å) were determined by molecular replacement utilizing the M102R mutant as a search model.

As suggested by its primary sequence (Fig 1A), QnrB1 folds as a right-handed quadrilateral β-helix. Each of the repeats assumes one face of an approximately regular quadrilateral (coil), with each coil rising roughly 4.8 Å (Fig 1B). There are a total of 10 coils, numbered 0 to 9, with full coils (four sides) for the body of the helix and partial coils at the termini (coil 0 and coil 9). The C-terminus is capped by a dimerization module, while the N-terminus is capped by non-typical PRP residues at the i⁻² position (E8, E18) with a salt bridge between Glu8 and Arg14 covering a portion of the bottom of β-helical coil 0. The C-terminus can be modeled by a dimerization module, which is common to all PRP:TPRFs, all PRP non-TPRFs determined to date are monomeric (37-39).

The structure of any PRP β-helix can be roughly modeled by analysis of the primary sequence, as its general features are known. What cannot be determined a priori is the type of hydrogen bonding between coils (isolated β-bridges or full β-sheet) and the structures of excursions from the typical PRP sequence. These excursions often affect the β-helical axis and/or produce loops that alter the sequential stacking order of the pentapeptides (34,37).

The structure of QnrB1 demonstrates that most of the coils are constructed from pentapeptides that take the type II turn conformation with an isolated β-bridge between...
coils (spheres in Fig 1B). There are a total of seven pentapeptides that are in the opposing conformation with type IV turns and full hydrogen bonding between coils (strands in Fig 1B). These are all located on faces 1 and 2 and are in the N-terminal portion of the β-helix. This theme is common among PRP-TPRFs in clustering of the type II-turn pentapeptides towards the C-terminal end. The type II-turn conformation condenses the pentapeptide by approximately 0.5 Å such that coils with a preponderance of type II turns have a smaller diameter (15 Å vs. 30 Å).

There are two loop excursions from the β-helix that protrude out into solvent. Loop A, connecting face 2 to face 3 on coil 2 (residues 46-53), and loop B, which connects face 4 to face 1 of coils 4 and 5 (residues 102-113) (Fig 1, Fig 2). The smaller A loop (8 vs 12 residues) is constructed with an isolated β-bridge (Asp47 to Lys52) and a 4-residue turn (Fig 2A,B), while the B loop is constructed of β-strands (M102,N103 to F111,C112) with connecting residues labeled as a “bend” by the secondary structure detection program DSSP (40) (Fig 2A,C). The loops form highly extended structures with the A and B loop projecting approximately 10 and 15 Å from the β-helix, respectively. In the QnrB1 wild type structure there are four copies in the asymmetric unit, and in all four copies the loops are in the same conformation indicating the observed conformation is encoded by the sequence and not an artifact of crystal packing. Loop A does not distort the interactions between coils 1, 2 and 3 on face 2 with only a 0.2-1.0 Å increase from the expected intercoil distances (~4.8 Å). The conformation of loop A is partially supported by the packing of the side chain of Asp47 against Phe26, the i+1 residue of coil 1, and the packing of the side chain of Tyr46 against Ser72 and Met73, the i+1 and i+2 residue of coil 3 (Fig 2B). In contrast, loop B has an approximate 2 Å increase from expected between coils 4 and 5 on face 4 with the packing of Met102 and Cys112 against Val130, the i+1 residue of coil 5, acting as a wedge. In addition, there is a hydrogen bond between the indole nitrogen of Trp110 and the side chain of E132, the i+1 residue of coil 5, that may anchor the loop conformation in relation to the β-helix. The wedging of the β-helix results in a change in the β-helical axis after the disruption and is reminiscent of a similar feature in the structures of MfpA (20) and AlbG (36). Examination of the trypsin treated M102R and the R167E structures suggest that the trypsinolysis occurred within loop B. There was continuous electron density in both structures for loop A, but missing electron density for residues in the B loop (M102R: A103-111, B108; R167E: A103-110, B103-110). The mutant structures also indicate that cleavage within the B loop did not affect the change in the β-helical axis between coils 4 and 5. Treatment of QnrB1 with trypsin resulted in a dramatic increase in protein solubility with trypsin-treated protein soluble to > 100 mg ml⁻¹. In addition, mutational deletion of either loop dramatically affected the ability of QnrB1 to rescue gyrase from fluoroquinolone inhibition (see below).

QnrB1 purified for this study did not inhibit the DNA supercoiling activity of E. coli gyrase up to 5 µM concentrations while it protected gyrase against ciprofloxacin similar to the results previously obtained for the in vitro activity of QnrB1 (10). 20 nM QnrB1 completely protected gyrase against 5 µM ciprofloxacin and partial protection was observed at 10 µM ciprofloxacin (Fig 3A). However, increased concentrations of QnrB1 (up to 200 nM) failed to provide complete protection to gyrase against ciprofloxacin concentrations above 5 µM (data not shown). The ability of the structure-based loop A deletion mutant (ΔY46:Q51) to rescue gyrase from ciprofloxacin decreased drastically. It partially rescued fluoroquinolone inhibition of gyrase (approximately 50% protection compared to wild type) at a concentration of 2 µM. Structure-based loop B deletion mutant (ΔM104-S113) and double deletion mutant (ΔY46-Q51, ΔM104-S113) QnrB1 completely lost the ability to protect gyrase against the inhibitory effects of ciprofloxacin (Fig 3B). None of the mutants inhibited the gyrase at concentrations as high as 5 µM (data not shown). QnrB1 failed to rescue novobiocin mediated ATPase activity inhibition of GyrB (Fig 3C). Up to 1 µM QnrB1 could not provide any detectable protection against 2 µM novobiocin (data not shown). In cleavage complex stabilization assay, 4 µM ciprofloxacin blocked more than 90% of gyrase activity while 16 µM completely blocked the gyrase activity with an increase in cleaved forms of DNA (Fig 3C). Presence of QnrB1 (200 nM), as determined by the formation of supercoiled DNA, reversed the
stabilization by approximately 80% and 30% against 4 and 16 µM ciprofloxacin, respectively (Figure 3C).

**DISCUSSION**

PRPs can currently be classified into three groups. The largest number of PRPs originates from cyanobacterial genomes, and several of their structures have been determined (37-39). These proteins conform fairly strictly to the PRP consensus sequence, are highly symmetrical being almost entirely composed of pentapeptides in the isolated β-bridge/type II-turn conformation, and have so far been found to be monomeric in structure. Versions with C-terminal α-helical capping (Rfr32(37)) and N-terminal α-helical capping (RR23(38), NP275/276(41), HetL(42)) have been observed, and several of these proteins contain loop excursions (HetL, Rfr23), although none drastically change the pitch of the β-helix. Their function has yet to be determined, though Rfr23 and HglK have been found to be involved in manganese uptake and heterocyst formation, respectively (42,43). The remaining PRPs fall into two groups, both of which have a topoisomerase poison resistance factor activity. In the first group are a number of chromosomally encoded enzymes that either have a known poison for which the PRP acts as a resistance factor or an unknown function with a side activity of reducing fluoroquinolone susceptibility. For example, the proteins MhpG and AlbG engender a self-resistance to the topoisomerase II poisons microcin B17 and albicidin (16,17), respectively; while the PRP proteins MfpA and EfsQRnR confer fluoroquinolone resistance but have no known cellular function (19,44). The structure of MfpA from *M. tuberculosis*, AlbG from *X. albilines*, and Qnr from *Enterococcus faecalis* (EfsQRnR) have been determined (Fig 1B) (20,36,45). Their unique features over the cyanobacterial PRPs include divergence from the consensus sequence, inclusion of more β-strand interactions between coils (type IV turns), alterations in the pitch of the β-helical axis, and inclusion of a dimerization module at the C-terminus. Despite their similarity in structure and the underlying constraints of the PRP consensus sequence, they exhibit low sequence identity (<25%). In the second group are a number of plasmid-based PRP-TPRFs that have collectively been called Qnr proteins. These proteins include QnrA, QnrB, QnrC, QnrD and QnrS, with sequence identities of > 30% between them and > 70% for allelic variants (4,13). Qnr proteins were originally recognized on resistance plasmids (5). Some plasmid-based PRP-TPRFs appear to have originated from the chromosomal pool of PRP-TPRFs. For example the chromosomally encoded protein Qnr from *Shewanella algae* (SaQnr) has > 98% amino acid identity with QnrA1 (46,47). The structure of QnrB1 determined here is the first from the plasmid-based PRP-TPRFs and highlights their similarity to the chromosomally encoded group. Like MfpA, AlbG and EfsQRnR, QnrB1 is a highly asymmetric dimer of similar dimensions, with a mix of type II and type IV turn pentapeptides. Like MfpA and AlbG, there is a helical kink between coils 4 and 5 on face 4, and in the case of AlbG a similarly located loop excursion.

**Conservation of Loops A and B** – Prior to the determination of the structure of QnrB1, it had been noted that a characteristic feature of Qnr proteins is that they are formed by two domains of pentapeptide repeats separated by a single amino acid, glycine, followed by a cysteine (1). Additional analysis of the predicted pentapeptide preceding the glycine reveals that there are non-typical PRP residues at the internal positions (i² and i). For example, in QnrB1 the i² residue is an arginine (Arg48) and the i residue is a serine (Ser50). A similar analysis of later repeats notes similar discontinuities for the i² and i residues of repeats approximately midway through the sequence. For example, the predicted i² residues Met104 and i residue Thr106 of QnrB1. However, this particular discontinuity is easily overlooked as there is not a disruption in the frame of five-residue elements between clearly defined pentapeptides. The structure of QnrB1 can now explain these discontinuities, with the former resulting in an 8-residue loop (Loop A) and the later a 12-residue loop (Loop B). Examination of all Qnr variants, including those chromosomally encoded PRPs with > 35% similarity with QnrB1, demonstrates the preservation of the A and B loops. However, only the B loop has any significant sequence conservation within the loop for QnrA, B, C, D, and S with a consensus sequence of (F)X(N)X(I/V)(S/T)XXX(W/F/Y)(F)(C)X(A/V)
A rescue model for PRP:TPRFs

Previously an inhibition model was proposed for the manner in which the chromosomally encoded pentapeptide repeat protein MfpA was able to engender a fluoroquinolone resistance phenotype (20). This model was based on biophysical data in which MfpA inhibited E. coli gyrase supercoiling with an IC50 of 1.2 µm, an inability of MfpA to rescue gyrase from fluoroquinolone inhibition, and the structure of MfpA, which had charge and shape characteristics reminiscent of B-form DNA. A convincing model of MfpA bound to the G-segment DNA binding saddle of gyrase was generated, suggesting that MfpA was outcompeting the generation of the initial gyrase-DNA complex. The binding of gyrase by MfpA would inhibit formation of the gyrase-covalent DNA-fluoroquinolone complex and thereby block the bacteriostatic (stalled ribosomes) and bactericidal (double strand breaks) effects of fluoroquinolones. The question can be asked, however, how the cell can function with an inhibited gyrase and, in such an inhibition model, how are PRPs regulated such that they are generated only when needed. Further problems with this model arose with the determination of the structures of several topoisomerase II enzymes with DNA bound to the DNA-gate. In these structures the DNA segment takes a highly bent conformation, with a central region located deep within the saddle to react with the active site tyrosines, exiting at a 150° angle along the topoisomerase II tower domains (48-52). It is doubtful that MfpA could be bent in a similar fashion as to make similar contacts with the DNA saddle.

The accumulation of data for a diverse set of PRP:TPRFs suggests the assay data for MfpA may be atypical of the family. QnrA1 at 320 nM was found to reverse 50% of gyrase inhibition by 1.5 µm ciprofloxacin, with no inhibition of gyrase at the highest QnrA1 concentrations tested (2.01 µM) (1-3). QnrB4 increased the IC50 of ciprofloxacin 5-fold at 0.5 µm and had protective effects as low as 100 nM (21). QnrB4 did not inhibit E. coli DNA gyrase supercoiling unless concentrations were at least as high as 30 µM. Similarly, QnrB1 at 0.5 nM was found to reverse 50% of ciprofloxacin (6 µM) inhibition of supercoiling with some protection even at 5 pM. Some inhibition of supercoiling was observed at the highest concentration tested (25 µM) (10). The chromosomally encoded PRP-TPRF, EfsQnr was found to protect gyrase against ciprofloxacin inhibition partially, and partial protection was observed even at the lowest tested concentration of 20 nM (44, 45). The determined IC50 value for gyrase inhibition by ciprofloxacin was 0.25 µM, while in the presence of 0.2 µM EfsQnr, the IC50 increased to 1.4 µM. Purified EfsQnr inhibited the ATP-dependent DNA supercoiling activity of E. coli gyrase with a calculated IC50 value of 1.2 µM. Finally, purified AlbG (0.65 µM) protected gyrase from the effects of albicidin in supercoiling assays, increasing the IC50 for albicidin by 2- to 4-fold, with little to no effect on the sensitivity to ciprofloxacin (16). AlbG partially inhibited the supercoiling activity of DNA gyrase in the absence of albicidin with an IC50 of 6 µM.

Taken together these results suggest that the main protective effect, which manifests in the phenotypic resistance to gyrase poisons, arises from the interaction of PRP-TPRFs at submicromolar concentrations with the topoisomerase-poison-cleavage complex. In the new model, the PRP-TPRFs act by binding to and destabilizing the topoisomerase-poison-cleavage complex, causing release of the poison and allowing religation and release of DNA. In this model, religation of the DNA would drive the release of the PRP-TPRF and regeneration of a catalytically active form of the topoisomerase.
Inhibition of gyrase at higher concentrations of PRP-TPRFS would be the byproduct of a weaker binding to the apo or DNA-bound topoisomerase. Type II topoisomerases contain two major catalytic components; energy transduction resulting from the ATP hydrolysis and DNA strand cleavage/religation that are carried out by different subunits. Topoisomerase inhibitors primarily inhibit either ATP hydrolysis or strand cleavage/religation. Fluoroquinolones primarily inhibit the strand cleavage/religation with a secondary ATPase inhibition while novobiocin and other aminocoumarins inhibit the ATPase activity. The experimental data obtained here for QnrB1 mediated rescue of gyrase activity further supports the above model. The inability of QnrB1 to rescue the gyrase from novobiocin inhibition rules out the possibility of QnrB1 protecting the gyrase from ATPase inhibition by quinolones. While the reversal of quinolone mediated cleavage complex stabilization by QnrB1 suggests that the gyrase protection activity of QnrB1 emanates from the destabilization of quinolone induced stabilization of the cleavage complex.

In general topoisomerase II-DNA complexes remain predominantly in the closed, uncleaved state, only progressing to the cleaved state upon interaction with a T-segment DNA (53). As such, the conformation of the topoisomerase which the PRP-TPRFS observe would not accumulate to levels sufficient for PRP-TPRF binding if PRP-TPRF levels are low. When topoisomerase II enzymes interact with topoisomerase poisons, the DNA-cleavage state is stabilized and accumulates to high levels such that low constitutively expressed PRP-TPRFS can act. We envision that the PRP-TPRFS are tuned to the specific conformation driven by the topoisomerase-toxin pair, such that there is both species specificity and poison specificity. PRP-TPRFS are ideal for evolutionary selection against protein-DNA interfaces, as they have an extended binding if PRP:TPRF levels are low. When primarily inhibit either ATP hydrolysis or strand binding to the apo or DNA-bound topoisomerase.

We envision that the PRP:TPRFs are tuned to the specific conformation driven by the topoisomerase-toxin pair, such that there is both species specificity and poison specificity. PRP-TPRFS are ideal for evolutionary selection against protein-DNA interfaces, as they have an extended binding if PRP:TPRF levels are low. When primarily inhibit either ATP hydrolysis or strand binding to the apo or DNA-bound topoisomerase.
REFERENCES


**FOOTNOTES**

*This work was supported in part by the grants R01AI033696 to J.S.B. and R01AI057576 to D.C.H and G.A.J.
The abbreviations used are: PRP, pentapeptide repeat protein; PRP-TPRF, pentapeptide repeat protein topoisomerase-poison resistance factors; DTPA, diethylenetriamine pentaacetic acid GdIII; SAD, single anomalous dispersion; *EfxQnr, Enterococcus faecalis* Qnr; *AhQnr, Aeromonas hydrophila* Qnr
FIGURE LEGENDS

Fig. 1. Structure of QnrB1 (A) Structure based PRP sequence diagram. The sequence of QnrB1 is segmented into four columns representing the four faces of the right handed quadrilateral β-helix. The face name and color are represented at the top followed by the naming convention for the five residues of the pentapeptide repeats. Loop A and loop B are indicated by one and two asterisks, respectively, with their sequences indicated below. The N-terminal α-helix is blocked in salmon color. (B) Monomer structure of QnrB1, MfpA, AlbG and EjsQnr in a similar orientation and colored by face. (C) Dimeric structure of QnrB1. The A and B loop of QnrB1 are shown as a black trace. The molecular two-fold is shown as a black diamond. Type II turn containing faces are shown as spheres, while type IV containing faces are shown as strands.

Fig. 2. The extruding loops of QnrB1 (A) Looking down the β-helix from C to N-terminus showing the position and the extended conformation the A and B loops take from the β-helix. (B) Stick representation of loop A. (C) Stick representation of loop B. Residues are colored by atom type. (D) Sequence alignment of loop A (top) and loop B (bottom) sequences of plasmid encoded (QnrA-S) and chromosomally encoded Qnr proteins. Sequences are highlighted based on a much larger sequence alignment created with the sequence conservation program CONSURF (55,56). Sequence positions that scored from 7-9 (out of 10) and that were labeled as conserved are highlighted in red. Outside of the loop structures (bounded by the asterisks), the sequences are sectioned as pentapeptides.

Fig. 3. Inhibition of DNA gyrase by ciprofloxacin/novobiocin and protection by QnrB1. (A) QnrB1 mediated protection of gyrase (supercoiling activity) against ciprofloxacin. Lanes are; relaxed plasmid pBR322 alone (1), relaxed pBR322 plus gyrase (2), relaxed pBR322, gyrase and 2 µM ciprofloxacin (3-7) in the presence of 20 nM QnrB1<sup>WT</sup> (4), 2 µM loop-AB double deletion (5), loop B deletion (6) and loop A deletion (7) mutants. (B) Concentration dependent inactivation of gyrase (supercoiling activity) by ciprofloxacin in the presence of QnrB1. Lanes are; relaxed plasmid pBR322 (1), relaxed pBR322 plus gyrase (2), relaxed pBR322, gyrase and 10 µM ciprofloxacin in the absence of QnrB1<sup>WT</sup> (3), and 2, 5, 10, 25 and 50 µM ciprofloxacin in the presence of 40 nM QnrB1<sup>WT</sup> (4-8), respectively. (C) Effect of QnrB1 on ATPase inhibition and cleavage complex stabilization. Lanes are; relaxed plasmid pBR322 (1), relaxed pBR322 plus gyrase (2), relaxed pBR322, gyrase and 2 µM novobiocin in the absence of QnrB1<sup>WT</sup> (3), and in the presence of 200 nM QnrB1<sup>WT</sup> (4), cleavage complex stabilization assays using 4 µM (4, 5) and 16 µM ciprofloxacin (7, 8) in the absence of QnrB1 (5, 7) and in the presence of 200 nM QnrB1 (6, 8), respectively. nc, l and sc are nicked circular, linear and supercoiled forms of pBR322, respectively.
Table 1. Data Collection and Refinement Statistics

<table>
<thead>
<tr>
<th>DATASET</th>
<th>NATIVE</th>
<th>M102R(^{\text{TRYPSIN}})</th>
<th>DTPA Derivative (\text{(M102R},\text{TRYPSIN}))</th>
<th>R167E(^{\text{TRYPSIN}})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Space Group</td>
<td>(P_{2,1,2,1})</td>
<td>I422</td>
<td>I422</td>
<td>P4(_1,2,2)</td>
</tr>
<tr>
<td>Unit Cell (Å, °)</td>
<td>(a=38.1, b=119.532, c=231.725)</td>
<td>(a=101.1, c=275.6)</td>
<td>(a=101.5, c=275.6)</td>
<td>(a=55.3, c=282.5)</td>
</tr>
<tr>
<td>Resolution (Å)</td>
<td>40-2.8 (2.8-2.95)</td>
<td>40-2.2 (2.24-2.2)</td>
<td>40-2.5 (2.64-2.5)</td>
<td>40-1.8 (1.9-1.8)</td>
</tr>
<tr>
<td>Completeness (%)</td>
<td>99.0 (98.2)</td>
<td>99.3 (99.5)</td>
<td>100.0 (100.0)</td>
<td>94.5 (75.3)</td>
</tr>
<tr>
<td>Redundancy</td>
<td>7.8 (7.4)</td>
<td>7.8 (7.7)</td>
<td>12.5 (11.7)</td>
<td>7.0 (2.7)</td>
</tr>
<tr>
<td>Mean(I)/sd(I)</td>
<td>18.7 (6.5)</td>
<td>27.0 (6.0)</td>
<td>19.4 (4.2)</td>
<td>19.3 (2.8)</td>
</tr>
<tr>
<td>(R_{\text{sym}})</td>
<td>0.077 (0.277)</td>
<td>0.060 (0.366)</td>
<td>0.084 (0.557)</td>
<td>0.061 (0.355)</td>
</tr>
<tr>
<td>Wilson B Factor (Å(^2))</td>
<td>39.6</td>
<td>36.0</td>
<td>56.4</td>
<td>15.7</td>
</tr>
</tbody>
</table>

Model and Refinement Data

| Resolution (Å) | 40-2.8 (2.9-2.8) | 40-2.2 (2.2-2.28) | 40-1.8 (1.8-1.86) |
| Unique reflections | 26120 (2734) | 35308 (3097) | 39399 (2492) |
| \(R_{\text{cryst}}\) (%) | 22.5 (33.9) | 19.3 (24.3) | 18.0 (23.8) |
| \(R_{\text{free}}\) (% of data) | 30.1 (46.6) | 22.2 (32.0) | 22.1 (30.0) |

Contents of model

- Residues (1-x): A1-210, B1-212, C4-212, D3-210
- Waters: 190
- Other: 10 (SO4x2)
- Atoms total: 6610
- 3505
- 3542
- Average B-factor (Å\(^2\))
- Protein/Waters: 38.1 / 40.5 / 64.2
- 17.9 / 26.1
- RMSD
- Bond lengths (Å)
  /Angles (°)
- 0.008 / 1.19
- 0.007 / 0.978
- 0.010 / 1.18
- MOLPROBITY Stats
- Ramachandran Favored / Outliers (%)
  90.3 / 0.24
  97.3 / 0.0
  99.0 / 0.0
- Rotamer Outliers (%)
  4.7
  0.87
  1.5
- Clashscore \(^{\text{b}}\)
  24.1 (81\(^{\text{st}}\) percentile)
  5.6 (98\(^{\text{th}}\) percentile)
  45.6 (97\(^{\text{th}}\) percentile)
- Overall score \(^{\text{b}}\)
  2.92 (71\(^{\text{st}}\) percentile)
  1.43 (99\(^{\text{th}}\) percentile)
  1.36 (97\(^{\text{th}}\) percentile)

\(^{a}\) Statistics in parenthesis are for the highest resolution bin

\(^{b}\) Scores are ranked according to structures of similar resolution as formulated in MOLPROBITY

* bijivolets merged
Figure 1

A

<table>
<thead>
<tr>
<th>N-term</th>
<th>Face1</th>
<th>Face2</th>
<th>Face3</th>
<th>Face4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coil0</td>
<td>MA</td>
<td>LALVG</td>
<td>EKIDR</td>
<td>NRTFG</td>
</tr>
<tr>
<td>Coil1</td>
<td>EKIE</td>
<td>SFFN</td>
<td>CDFTG</td>
<td>ADFS</td>
</tr>
<tr>
<td>Coil2</td>
<td>TEFIG</td>
<td>CFQF</td>
<td>CNFSR</td>
<td>AMLKD</td>
</tr>
<tr>
<td>Coil3</td>
<td>AIFKS</td>
<td>CDLSM</td>
<td>ADFRN</td>
<td>SSSLG</td>
</tr>
<tr>
<td>Coil4</td>
<td>IEIRH</td>
<td>CRAQG</td>
<td>ADFRG</td>
<td>ASF **</td>
</tr>
<tr>
<td>Coil5</td>
<td>AYTIN</td>
<td>TNLST</td>
<td>ANFSK</td>
<td>VVELK</td>
</tr>
<tr>
<td>Coil6</td>
<td>CELWE</td>
<td>NRWIG</td>
<td>AQVLTG</td>
<td>ATFS</td>
</tr>
<tr>
<td>Coil7</td>
<td>SDLTG</td>
<td>GEFST</td>
<td>FDWRA</td>
<td>ANFTH</td>
</tr>
<tr>
<td>Coil8</td>
<td>CDLTN</td>
<td>SELGD</td>
<td>LDIRG</td>
<td>VDLQG</td>
</tr>
<tr>
<td>Coil9</td>
<td>VKLDN</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Loop A (*) 46 YDESQKG 53
Loop B (**) 102 MNMITTRTFCS 113

B

C

102-113

N-term

Coil B

Coil A

Coil 9 (C9)

Coil 8

Coil 7

Coil 6

Coil 5

Coil 4

Coil 3

Coil 2

Coil 1

C-term

QnrB1

MfpA

AlbG

EfsQnR

p91

4-53

62-113

102-113

Coil 8

Coil 7

Coil 6

Coil 5

Coil 4

Coil 3

Coil 2

Coil 1

N-terminal Extension

N-term

Subunit B

Loop B' 102-113

Loop A' 46-53

Subunit A

Loop A 46-53

Loop B 102-113

C-term

α1

α1'

Subunit A

N-term'
Figure 3
Structure of QnrB1, a plasmid-mediated fluoroquinolone resistance factor
Matthew W. Vetting, Subray S. Hegde, Minghua Wang, George A. Jacoby, David C.
Hooper and John S. Blanchard

J. Biol. Chem. published online May 19, 2011

Access the most updated version of this article at doi: 10.1074/jbc.M111.226936

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 0 references, 0 of which can be accessed free at
http://www.jbc.org/content/early/2011/05/19/jbc.M111.226936.full.html#ref-list-1